(NASDAQ: RZLT) Rezolute's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Rezolute's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast RZLT's revenue for 2026 to be $147,697,341, with the lowest RZLT revenue forecast at $124,418,956, and the highest RZLT revenue forecast at $170,975,726. On average, 2 Wall Street analysts forecast RZLT's revenue for 2027 to be $2,001,339,105, with the lowest RZLT revenue forecast at $982,508,399, and the highest RZLT revenue forecast at $3,020,169,812.
In 2028, RZLT is forecast to generate $9,626,214,332 in revenue, with the lowest revenue forecast at $6,940,570,971 and the highest revenue forecast at $12,311,857,694.